Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.58)
# 859
Out of 5,043 analysts
432
Total ratings
46.2%
Success rate
10.6%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Reiterated: Buy | $21 | $12.08 | +73.84% | 8 | Oct 9, 2026 | |
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $65 | $37.22 | +74.64% | 1 | Oct 9, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $18 | $3.22 | +459.01% | 22 | Sep 29, 2026 | |
| ACAD Acadia Pharmaceuticals | Reiterated: Buy | $36 | $19.78 | +82.00% | 56 | Sep 25, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $64 → $78 | $36.90 | +111.38% | 21 | Sep 15, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $20 | $12.00 | +66.67% | 27 | Sep 10, 2026 | |
| ANVS Annovis Bio | Reiterated: Buy | $17 | $1.21 | +1,304.96% | 12 | Aug 18, 2026 | |
| STOK Stoke Therapeutics | Reiterated: Buy | $58 | $24.74 | +134.44% | 18 | Aug 12, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $12 | $2.45 | +389.80% | 41 | Aug 12, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $20 | $11.39 | +75.59% | 20 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $21.11 | +84.75% | 18 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $210 | $142.44 | +47.43% | 42 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $245 → $248 | $225.71 | +9.88% | 84 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $24 | $8.83 | +171.80% | 3 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $3.86 | +1,195.34% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $1.03 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $12 | $31.73 | n/a | 12 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $31.18 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $17.64 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $19.91 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $15.06 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $193.70 | $8.64 | n/a | 7 | Dec 18, 2015 |
Biohaven
Oct 9, 2026
Reiterated: Buy
Price Target: $21
Current: $12.08
Upside: +73.84%
LB Pharmaceuticals
Oct 9, 2026
Initiated Coverage: Buy
Price Target: $65
Current: $37.22
Upside: +74.64%
CervoMed
Sep 29, 2026
Reiterated: Buy
Price Target: $18
Current: $3.22
Upside: +459.01%
Acadia Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $36
Current: $19.78
Upside: +82.00%
Definium Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $64 → $78
Current: $36.90
Upside: +111.38%
COMPASS Pathways
Sep 10, 2026
Reiterated: Buy
Price Target: $20
Current: $12.00
Upside: +66.67%
Annovis Bio
Aug 18, 2026
Reiterated: Buy
Price Target: $17
Current: $1.21
Upside: +1,304.96%
Stoke Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $58
Current: $24.74
Upside: +134.44%
Voyager Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $12
Current: $2.45
Upside: +389.80%
Zevra Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $20
Current: $11.39
Upside: +75.59%
Aug 6, 2026
Reiterated: Buy
Price Target: $39
Current: $21.11
Upside: +84.75%
Aug 3, 2026
Reiterated: Buy
Price Target: $200 → $210
Current: $142.44
Upside: +47.43%
Jul 30, 2026
Reiterated: Buy
Price Target: $245 → $248
Current: $225.71
Upside: +9.88%
Jul 27, 2026
Reiterated: Buy
Price Target: $35 → $24
Current: $8.83
Upside: +171.80%
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $3.86
Upside: +1,195.34%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $1.03
Upside: n/a
Jan 28, 2022
Downgraded: Hold
Price Target: $75 → $12
Current: $31.73
Upside: n/a
Apr 9, 2018
Reiterated: Hold
Price Target: n/a
Current: $31.18
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $17.64
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $19.91
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $15.06
Upside: n/a
Dec 18, 2015
Reiterated: Buy
Price Target: $193.70
Current: $8.64
Upside: n/a